Listen in and find out:
Generex Biotechnology Announces Investor Conference Call Scheduled for
Friday February 5, 2021 at 9:00 AM
MIRAMAR, FL, January 08, 2021/ -- Generex Biotechnology Corporation
(www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor
conference call on Friday February 5, 2021 at 9:00 AM.
Joseph Moscato, Generex President & Chief Executive Officer stated: “I am excited to
give our first shareholder conference call to update investors about the development of
our Ii-Key complete vaccine against the SARS-CoV-2 coronavirus that continues to
ravage the world. We have completed our ex vivo human trial of COVID-19 patient
samples and can confirm that the results of the T cell activation and antibody screen
have enabled us to select Ii-Key-SARS-CoV-2 epitopes for our vaccine formulation. I will
provide an update on these results as well as the results of our ongoing immunogenicity
study that will confirm the commercial viability of our Ii-Key vaccine. In addition, I will
update everyone on our progress and timing on the NuGenerex Immuno-Oncology
Nasdaq listing now that our third-party valuation analysis has been completed with a
value estimated at over $500 million. This third-party valuation report is the last piece of
information required to enable us to set the price per share to meet the standards for
the Nasdaq. I will also provide a complete corporate update including discussions of our
subsidiaries”
AI
Market Data 
Markets 
